PIGN encephalopathy: Characterizing the epileptology.

GPI-anchoring disorder congenital disorder of glycosylation developmental and epileptic encephalopathy epilepsy intellectual disability

Journal

Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R

Informations de publication

Date de publication:
04 2022
Historique:
revised: 12 01 2022
received: 05 10 2021
accepted: 12 01 2022
pubmed: 19 2 2022
medline: 14 4 2022
entrez: 18 2 2022
Statut: ppublish

Résumé

Epilepsy is common in patients with PIGN diseases due to biallelic variants; however, limited epilepsy phenotyping data have been reported. We describe the epileptology of PIGN encephalopathy. We recruited patients with epilepsy due to biallelic PIGN variants and obtained clinical data regarding age at seizure onset/offset and semiology, development, medical history, examination, electroencephalogram, neuroimaging, and treatment. Seizure and epilepsy types were classified. Twenty six patients (13 female) from 26 families were identified, with mean age 7 years (range = 1 month to 21 years; three deceased). Abnormal development at seizure onset was present in 25 of 26. Developmental outcome was most frequently profound (14/26) or severe (11/26). Patients presented with focal motor (12/26), unknown onset motor (5/26), focal impaired awareness (1/26), absence (2/26), myoclonic (2/26), myoclonic-atonic (1/26), and generalized tonic-clonic (2/26) seizures. Twenty of 26 were classified as developmental and epileptic encephalopathy (DEE): 55% (11/20) focal DEE, 30% (6/20) generalized DEE, and 15% (3/20) combined DEE. Six had intellectual disability and epilepsy (ID+E): two generalized and four focal epilepsy. Mean age at seizure onset was 13 months (birth to 10 years), with a lower mean onset in DEE (7 months) compared with ID+E (33 months). Patients with DEE had drug-resistant epilepsy, compared to 4/6 ID+E patients, who were seizure-free. Hyperkinetic movement disorder occurred in 13 of 26 patients. Twenty-seven of 34 variants were novel. Variants were truncating (n = 7), intronic and predicted to affect splicing (n = 7), and missense or inframe indels (n = 20, of which 11 were predicted to affect splicing). Seven variants were recurrent, including p.Leu311Trp in 10 unrelated patients, nine with generalized seizures, accounting for nine of the 11 patients in this cohort with generalized seizures. PIGN encephalopathy is a complex autosomal recessive disorder associated with a wide spectrum of epilepsy phenotypes, typically with substantial profound to severe developmental impairment.

Identifiants

pubmed: 35179230
doi: 10.1111/epi.17173
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

974-991

Informations de copyright

© 2022 International League Against Epilepsy.

Références

Hong Y, Maeda Y, Watanabe R, Ohishi K, Mishkind M, Riezman H, et al. Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol. J Biol Chem. 1999;274:35099-106.
Bellai-Dussault K, Nguyen TTM, Baratang NV, Jimenez-Cruz DA, Campeau PM. Clinical variability in inherited glycosylphosphatidylinositol deficiency disorders. Clin Genet. 2019;95:112-21.
Fujita M, Kinoshita T. GPI-anchor remodeling: potential functions of GPI-anchors in intracellular trafficking and membrane dynamics. Biochim Biophys Acta. 2012;1821:1050-8.
Guerrero PA, Murakami Y, Malik A, Seeberger PH, Kinoshita T, Varon SD. Rescue of glycosylphosphatidylinositol-anchored protein biosynthesis using synthetic glycosylphosphatidylinositol oligosaccharides. ACS Chem Biol. 2021;16(11):2297-306.
Ihara S, Nakayama S, Murakami Y, Suzuki E, Asakawa M, Kinoshita T, et al. PIGN prevents protein aggregation in the endoplasmic reticulum independently of its function in the GPI synthesis. J Cell Sci. 2017;130:602-13.
Teye EK, Lu S, Chen F, Yang W, Abraham T, Stairs DB, et al. PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression. Sci Rep. 2021;11:19022.
Lee JJY, Wasserman WW, Hoffmann GF, van Karnebeek CDM, Blau N. Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism. Genet Med. 2018;20:151-8.
Alessandri JL, Gordon CT, Jacquemont ML, Gruchy N, Ajeawung NF, Benoist G, et al. Recessive loss of function PIGN alleles, including an intragenic deletion with founder effect in La Reunion Island, in patients with Fryns syndrome. Eur J Hum Genet. 2018;26:340-9.
Ohba C, Okamoto N, Murakami Y, Suzuki Y, Tsurusaki Y, Nakashima M, et al. PIGN mutations cause congenital anomalies, developmental delay, hypotonia, epilepsy, and progressive cerebellar atrophy. Neurogenetics. 2014;15:85-92.
Khayat M, Tilghman JM, Chervinsky I, Zalman L, Chakravarti A, Shalev SA. A PIGN mutation responsible for multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1) in an Israeli-Arab family. Am J Med Genet A. 2016;170A:176-82.
Couser NL, Masood MM, Strande NT, Foreman AK, Crooks K, Weck KE, et al. The phenotype of multiple congenital anomalies-hypotonia-seizures syndrome 1: report and review. Am J Med Genet A. 2015;167A:2176-81.
Nakagawa T, Taniguchi-Ikeda M, Murakami Y, Nakamura S, Motooka D, Emoto T, et al. A novel PIGN mutation and prenatal diagnosis of inherited glycosylphosphatidylinositol deficiency. Am J Med Genet A. 2016;170A:183-8.
Maydan G, Noyman I, Har-Zahav A, Neriah ZB, Pasmanik-Chor M, Yeheskel A, et al. Multiple congenital anomalies-hypotonia-seizures syndrome is caused by a mutation in PIGN. J Med Genet. 2011;48:383-9.
Xu YF, Li N, Li GQ, Wang XM, Zhou YF, Yin L, et al. Multiple congenital anomalies-hypotonia-seizures syndrome 1: case report and review of literature. Zhonghua Er Ke Za Zhi. 2017;55:215-9.
Thiffault I, Zuccarelli B, Welsh H, Yuan X, Farrow E, Zellmer L, et al. Hypotonia and intellectual disability without dysmorphic features in a patient with PIGN-related disease. BMC Med Genet. 2017;18:124.
Fleming L, Lemmon M, Beck N, Johnson M, Mu W, Murdock D, et al. Genotype-phenotype correlation of congenital anomalies in multiple congenital anomalies hypotonia seizures syndrome (MCAHS1)/PIGN-related epilepsy. Am J Med Genet A. 2016;170A:77-86.
Xiao SQ, Li MH, Meng YL, Li C, Huang HL, Liu CX, et al. Case report: compound heterozygous phosphatidylinositol-glycan biosynthesis class N (PIGN) mutations in a Chinese fetus with hypotonia-seizures syndrome 1. Front Genet. 2020;11:594078.
Jiao X, Xue J, Gong P, Bao X, Wu Y, Zhang Y, et al. Analyzing clinical and genetic characteristics of a cohort with multiple congenital anomalies-hypotonia-seizures syndrome (MCAHS). Orphanet J Rare Dis. 2020;15:78.
Pagnamenta AT, Murakami Y, Taylor JM, Anzilotti C, Howard MF, Miller V, et al. Analysis of exome data for 4293 trios suggests GPI-anchor biogenesis defects are a rare cause of developmental disorders. Eur J Hum Genet. 2017;25:669-79.
Jezela-Stanek A, Ciara E, Piekutowska-Abramczuk D, Trubicka J, Jurkiewicz E, Rokicki D, et al. Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor biosynthesis-the phenotype of two patients with novel mutations in the PIGN and PGAP2 genes. Eur J Paediatr Neurol. 2016;20:462-73.
Pronicka E, Piekutowska-Abramczuk D, Ciara E, Trubicka J, Rokicki D, Karkucinska-Wieckowska A, et al. New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre. J Transl Med. 2016;14:174.
Xue S, Yan H, Chen J, Li N, Wang J, Liu Y, et al. Genetic examination for fetuses with increased fetal nuchal translucency by genomic technology. Cytogenet Genome Res. 2020;160:57-62.
De Giorgis V, Paoletti M, Varesio C, Gana S, Rognone E, Dallavalle G, et al. Novel insights into the clinico-radiological spectrum of phenotypes associated to PIGN mutations. Eur J Paediatr Neurol. 2021;33:21-8.
Sun L, Yang X, Xu Y, Sun S, Wu Q. Prenatal diagnosis of familial recessive PIGN mutation associated with multiple anomalies: a case report. Taiwan J Obstet Gynecol. 2021;60:530-3.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928-30.
Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2013.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82.
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-21.
Zhou W, Chen T, Chong Z, Rohrdanz MA, Melott JM, Wakefield C, et al. TransVar: a multilevel variant annotator for precision genomics. Nat Methods. 2015;12:1002-3.
Ng PC, Henikoff SSIFT. Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812-4.
Yu H, He X, Liu X, Zhang H, Shen Z, Shi Y, et al. A novel missense variant in cathepsin C gene leads to PLS in a Chinese patient: a case report and literature review. Mol Genet Genomic Med. 2021;5:e1686.
Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310-5.
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434-43.
Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535-48.e24.
Gelfman S, Wang Q, McSweeney KM, Ren Z, La Carpia F, Halvorsen M, et al. Annotating pathogenic non-coding variants in genic regions. Nat Commun. 2017;8:236.
Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
Scheffer IE, Liao J. Deciphering the concepts behind “epileptic encephalopathy” and “developmental and epileptic encephalopathy”. Eur J Paediatr Neurol. 2020;24:11-4.
Howell KB, Freeman JL, Mackay MT, Fahey MC, Archer J, Berkovic SF, et al. The severe epilepsy syndromes of infancy: a population-based study. Epilepsia. 2021;62:358-70.
Burgess R, Wang S, McTague A, Boysen KE, Yang X, Zeng Q, et al. The genetic landscape of epilepsy of infancy with migrating focal seizures. Ann Neurol. 2019;86:821-31.
Wilson MP, Plecko B, Mills PB, Clayton PT. Disorders affecting vitamin B6 metabolism. J Inherit Metab Dis. 2019;42:629-46.
Hassel B, Rogne AG, Hope S. Intellectual disability associated with pyridoxine-responsive epilepsies: the need to protect cognitive development. Front Psychiatry. 2019;10:116.
Kuki I, Takahashi Y, Okazaki S, Kawawaki H, Ehara E, Inoue N, et al. Vitamin B6-responsive epilepsy due to inherited GPI deficiency. Neurology. 2013;81:1467-9.
Bayat A, Klovgaard M, Johannesen KM, Stefan Barakat T, Kievit A, Montomoli M, et al. Deciphering the premature mortality in PIGA-CDG-an untold story. Epilepsy Res. 2020;170:106530.
Vogt M, Girschick H, Schweitzer T, Benoit C, Holl-Wieden A, Seefried L, et al. Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. Orphanet J Rare Dis. 2020;15:212.
Um JW, Ko J. Neural glycosylphosphatidylinositol-anchored proteins in synaptic specification. Trends Cell Biol. 2017;27:931-45.
Taketani T. Neurological symptoms of hypophosphatasia. Subcell Biochem. 2015;76:309-22.
Nguyen TTM, Murakami Y, Wigby KM, Baratang NV, Rousseau J, St-Denis A, et al. Mutations in PIGS, encoding a GPI transamidase, cause a neurological syndrome ranging from fetal akinesia to epileptic encephalopathy. Am J Hum Genet. 2018;103:602-11.
Sakaguchi T, Zigman T, Petkovic Ramadza D, Omerza L, Puseljic S, Eres Hrvacanin Z, et al. A novel PGAP3 mutation in a Croatian boy with brachytelephalangy and a thin corpus callosum. Hum Genome Var. 2018;5:18005.
Tanigawa J, Nabatame S, Tominaga K, Nishimura Y, Maegaki Y, Kinosita T, et al. High-dose pyridoxine treatment for inherited glycosylphosphatidylinositol deficiency. Brain Dev. 2021;43(6):680-7.

Auteurs

Allan Bayat (A)

Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark.
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.

Guillem de Valles-Ibáñez (G)

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.

Manuela Pendziwiat (M)

Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian Albrecht University, Kiel, Germany.
Institute of Clinical Molecular Biology, Christian Albrecht University of Kiel, Kiel, Germany.

Alexej Knaus (A)

Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Rhenish Friedrich Wilhelm University of Bonn, Bonn, Germany.

Kerstin Alt (K)

Center for Human Genetics, Neu-Ulm, Germany.

Elisa Biamino (E)

Department of Pediatrics, Regina Margherita Children's Hospital, Turin, Italy.

Annette Bley (A)

University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sophie Calvert (S)

Department of Neurosciences, Queensland Children's Hospital, South Brisbane, Queensland, Australia.

Patrick Carney (P)

Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.

Alfonso Caro-Llopis (A)

Genomics Unit, University and Polytechnic Hospital La Fe, Valencia, Spain.

Berten Ceulemans (B)

Department of Pediatric Neurology, Antwerp University Hospital, Edegem, Belgium.

Janice Cousin (J)

Section of Human Biochemical Genetics, National Human Genome Research Institute, Bethesda, Maryland, USA.

Suzanne Davis (S)

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.

Vincent des Portes (V)

Department of Neuropediatrics, Lyon University Hospital, Lyon, France.

Patrick Edery (P)

Department of Medical Genetics, University Hospital of Lyon, Lyon, France.

Eleina England (E)

Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.

Carlos Ferreira (C)

National Human Genome Research Institute, Bethesda, Maryland, USA.

Jeremy Freeman (J)

Royal Children's Hospital, Parkville, Victoria, Australia.
Murdoch Children's Research Institute, Parkville, Victoria, Australia.

Blanca Gener (B)

Department of Genetics, Cruces University Hospital, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Magali Gorce (M)

Angers University Hospital, Angers, France.

Delphine Heron (D)

Department of Genetics, Intellectual Disability and Autism Clinical Research Group, Pierre and Marie Curie University, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Paris, France.

Michael S Hildebrand (MS)

Royal Children's Hospital, Florey institute and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Epilepsy Research Centre, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia.

Aleksandra Jezela-Stanek (A)

Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.

Pierre-Simon Jouk (PS)

Inserm U1209, Grenoble Alpes University Hospital Center, University of Grenoble Alpes, Grenoble, France.

Boris Keren (B)

Department of Genetics, Intellectual Disability and Autism Clinical Research Group, Pierre and Marie Curie University, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Paris, France.

Katja Kloth (K)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Gerhard Kluger (G)

Center for Human Genetics, Neu-Ulm, Germany.

Marius Kuhn (M)

Center for Human Genetics, Neu-Ulm, Germany.

Johannes R Lemke (JR)

Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Center for Rare Diseases, University of Leipzig Medical Center, Leipzig, Germany.

Hong Li (H)

Emory University School of Medicine, Atlanta, Georgia, USA.

Francisco Martinez (F)

Genomics Unit, University and Polytechnic Hospital La Fe, Valencia, Spain.

Caroline Maxton (C)

Clinic for Pediatric Neurology, Hamburg, Germany.

Heather C Mefford (HC)

Center for Pediatric Neurological Disease Research, Department of Cell and Molecular Biology, St, Jude Children's Research Hospital, Memphis, Tennessee, USA.

Giuseppe Merla (G)

Department of Pediatrics, Regina Margherita Children's Hospital, Turin, Italy.

Hanna Mierzewska (H)

Department of Child and Adolescent Neurology, Institute of Mother and Child, Warsaw, Poland.

Alison Muir (A)

Center for Pediatric Neurological Disease Research, Department of Cell and Molecular Biology, St, Jude Children's Research Hospital, Memphis, Tennessee, USA.

Sandra Monfort (S)

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

Joost Nicolai (J)

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

Jennifer Norman (J)

INTEGRIS Pediatric Neurology, Oklahoma City, Oklahoma, USA.

Gina O'Grady (G)

Starship Children's Hospital, Auckland, New Zealand.

Barbara Oleksy (B)

Center for Child and Adolescent Medicine, Pediatric Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Carmen Orellana (C)

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

Laura Elena Orec (LE)

Department of Medical Genetics, Children's Memorial Health Institute, Warsaw, Poland.

Charlotte Peinhardt (C)

Emory University School of Medicine, Atlanta, Georgia, USA.

Ewa Pronicka (E)

Clinical Genetics, La Paz University Hospital, Madrid, Spain.

Monica Rosello (M)

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

Fernando Santos-Simarro (F)

Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.

Eva Maria Christina Schwaibold (EMC)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.

Alexander P A Stegmann (APA)

Department of Clinical Genetics and School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.

Constance T Stumpel (CT)

Department of Genetics, University of Bourgogne-Franche Comté, Dijon, France.

Elzbieta Szczepanik (E)

Center for Child and Adolescent Medicine, Pediatric Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Iwona Terczyńska (I)

Institute of Clinical Genetics, Dresden University of Technology, Dresden, Germany.

Julien Thevenon (J)

Neurology Department, University Hospital Antwerp, Antwerp, Belgium.

Andreas Tzschach (A)

Applied and Translational Genomics Group, Center for Molecular Neurology, University of Antwerp, Antwerp, Belgium.

Patrick Van Bogaert (P)

Angers University Hospital, Angers, France.

Roberta Vittorini (R)

Department of Pediatrics, Regina Margherita Children's Hospital, Turin, Italy.

Sonja Walsh (S)

Applied and Translational Genomics Group, Center for Molecular Neurology, University of Antwerp, Antwerp, Belgium.

Sarah Weckhuysen (S)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.
Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.

Barbara Weissman (B)

Department of Medical Genetics, Children's Memorial Health Institute, Warsaw, Poland.

Lynne Wolfe (L)

National Human Genome Research Institute, Bethesda, Maryland, USA.

Alexandre Reymond (A)

Giannina Gaslini Institute, Genoa, Italy.

Pasquelena De Nittis (P)

Giannina Gaslini Institute, Genoa, Italy.

Annapurna Poduri (A)

Departments of Medicine and Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.

Heather Olson (H)

Departments of Medicine and Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.

Pasquale Striano (P)

Giannina Gaslini Institute, Genoa, Italy.

Gaetan Lesca (G)

Department of Medical Genetics, University Hospital of Lyon, Lyon, France.

Ingrid E Scheffer (IE)

Royal Children's Hospital, Florey institute and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Departments of Medicine and Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.

Rikke S Møller (RS)

Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark.
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.

Lynette G Sadleir (LG)

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH